Interleukin-2: Biology, Design and Application

Arenas-Ramirez, Natalia; Woytschak, Janine; Boyman, Onur

doi:10.1016/j.it.2015.10.003

Cited by 306 publications

(301 citation statements)

References 83 publications

Supporting

Mentioning

292

Contrasting

Unclassified

Order By: Relevance

“…In this study, there were no statistically significant changes in IL-2, IL-6 or IL-10 levels in any of the groups (Table 1). IL-2 may have an antitumor effect (Arenas-Ramirez et al, 2015) and levels of IL-2 decrease in colon cancer (Baier et al, 2005). However, HLF may increase IL-2 levels (Jin et al, 2014).…”

Section: Resultsmentioning

confidence: 99%

Halofuginone may suppresses azoxymethane-induced serum tumor necrosis factor-a synthesis and aberrant crypt foci progression in rat colon

Çorum

Yazar

2017

IJAR

View full text Add to dashboard Cite

The aim of this research was to investigate the effect of halofuginone on the progression of azoxymethane-induced colon cancer in rats. A total of 38 male Wistar albino rats were divided into 4 groups: Control (n=8), Halofuginone (n=10, 0.4 mg/ kg, PO, SID), Cancer (n=10, azoxymethane, 15 mg/kg, IP, once a week for two weeks) and Cancer + Halofuginone (n=10). After 18 weeks, blood samples were taken under anesthesia and all animals were sacrificed. Aberrant crypt foci in the colon were stained with methylene blue. Blood cytokines, thiobarbituric acid reactive substances, 13,14-dihydro-15-ketoprostaglandin F2 levels, hemogram and biochemical values were measured. The tumor necrosis factor-a level in the Cancer group was higher (P<0.05) than in other groups, while higher numbers of aberrant crypt foci were found in the Cancer group compared with the Cancer + Halofuginone group (P<0.05). In summary, it may be stated that halofuginone may warrant evaluation as a supportive drug in the treatment of colon cancer in the future.

show abstract

Section: Resultsmentioning

confidence: 99%

Halofuginone may suppresses azoxymethane-induced serum tumor necrosis factor-a synthesis and aberrant crypt foci progression in rat colon

Çorum

Yazar

2017

IJAR

View full text Add to dashboard Cite

show abstract

“…In low doses, IL-2 is the cytokine responsible for immunosuppressive effects [22]. T. populinum could exhibit such an effect by decreasing IL-2 concentrations in biological systems.…”

Section: Discussionmentioning

confidence: 99%

Effects of extracts and compounds from Tricholoma populinum Lange on degranulation and IL-2/IL-8 secretion of immune cells

Merdivan

Jenett‐Siems

Siems³

et al. 2017

Zeitschrift Für Naturforschung C

View full text Add to dashboard Cite

Tricholoma populinum Lange is an edible basidiomycete from the family Tricholomataceae. Extracts, fractions, and different metabolites isolated from the fruiting bodies of this mushroom were tested for degranulationinhibiting activities on RBL-2H3 cells (rat basophils). Dichloromethane extracts decreased degranulation significantly, as did a fraction after column chromatography. In addition, the extract decreased the IL-2 release from Jurkat T cells and the release of IL-8 from HMC-1 human mast cells. The results show the significant effects of extracts of T. populinum on cells of the innate (basophils and mast cells) and adaptive (T cells) immune system and indicate the influence of the mushroom on different immunological processes. As one fraction showed activity, it seems to be possible that it includes an active principle. The compounds responsible for this effect, however, could not be identified as the contents oleic acid (1), ergosterol peroxide (2), and 9,11-dehydroergosterol peroxide (3) showed no effects. Nevertheless, the mushroom could be used for supporting allergy treatment in future studies.

show abstract

“…[11] Monomeric IL-2Rs, comprising only CD25, also exist in membrane-bound or soluble forms. Since CD25 is not involved in signaling these receptors are thought to function as scavengers for IL-2, reducing free IL-2 levels or trans-presenting bound IL-2 to effector T cells.…”

Section: The Biology Of Il-2mentioning

confidence: 99%

“…[ [55][56][57] Other strategies of selective IL-2 immunotherapy consist in the design of IL-2 muteins where specific amino acid substitutions are introduced to favor or disfavor the binding of IL-2 to certain IL-2R subunits (reviewed in [11] ). These IL-2 muteins, however, appear to be immunogenic, thus eliciting anti-drug antibodies that interfere with the activity of IL-2 muteins.…”

Section: Concluding Commentsmentioning

confidence: 99%

Interleukin-2 Immunotherapy for Advanced Cancer

Şahin¹,

Boyman²

2017

Turk J Immunol

Self Cite

View full text Add to dashboard Cite

Interleukin-2 (IL-2) was the first approved immunotherapy to show efficacy in advanced cancer. 13-20% of patients with metastatic renal cell carcinoma and metastatic melanoma receiving high-dose IL-2 treatment showed objective clinical responses, some enduring for up to 20 years and more. However, the use of IL-2 immunotherapy was hampered by the short in vivo half-life of IL-2, dose-dependent toxicity and stimulation of immunosuppressive regulatory T cells. Recent efforts have explored the biology of IL-2 and its receptors to generate improved IL-2 formulations. Such IL-2 formulations provide targeted and potent stimulation of selected lymphocyte subsets, and they include IL-2/ anti-IL-2 monoclonal antibody complexes (briefly, IL-2 complexes), IL-2 muteins, and versions of IL-2 bound to polyethylene glycol or other molecules. In this article, we review the use of IL-2 for cancer immunotherapy, and discuss the preclinical and translational aspects of IL-2 complexes and their potential for the treatment of advanced cancer. Keywords: Interleukin-2 (IL-2), immunotherapy, advanced cancer, tumor immunology ÖzInterlökin-2 (IL-2), ileri evre kanser vakalarında etkisi kanıtlanan ve tedavi için onaylanan ilk immünoterapi stratejisidir. Yüksek doz IL-2 tedavisi gören metastatik renal hücreli karsinom ve metastatik melanom hasarının %13-20'sinde tedaviye objektif yanıt alınmış ve hastaların bir bölümünde hastalıksız sağkalım 20 yılı aşmıştır. Ancak, IL-2 immünoterapisinin kullanımı, in vivo yarı-ömrünün kısa olması, doza bağlı toksisite ve immünosupresif düzenleyici T hücrelerinin stimülasyonu nedeniyle yaygınlaşmamıştır. IL-2 ve IL-2 reseptörlerindeki ilerleyen güncel çalışmalar sonucunda, geliştirilmiş IL-2 formülasyonları üretilmiştir. Bu formülasyonlar, IL-2/anti-IL-2 monoklonal antikor kompleksleri (kısaca, IL-2 kompleksleri), IL-2 muteinleri ve IL-2'nin polietilen glikol ve benzeri moleküllere bağlanmasını içermekte ve seçilmiş lenfosit alt-gruplarının selektif ve güçlü stimülasyonunu sağlamaktadır. Bu makalede, IL-2'nin kanser immünoterapisindeki rolü özetlenmekte ve IL-2 komplekslerinin klinik-öncesi çalışmaları ile kanser tedavisindeki potansiyeli tartışılmaktadır.Anahtar Kelimeler: Interlökin-2 (IL-2), immünoterapi, ileri evre kanser, tümör immünolojisi

show abstract

Interleukin-2: Biology, Design and Application

Cited by 306 publications

References 83 publications

Halofuginone may suppresses azoxymethane-induced serum tumor necrosis factor-a synthesis and aberrant crypt foci progression in rat colon

Halofuginone may suppresses azoxymethane-induced serum tumor necrosis factor-a synthesis and aberrant crypt foci progression in rat colon

Effects of extracts and compounds from Tricholoma populinum Lange on degranulation and IL-2/IL-8 secretion of immune cells

Interleukin-2 Immunotherapy for Advanced Cancer

Contact Info

Product

Resources

About